3D Signatures Inc. has announced the initiation of validation program for its Hodgkin's lymphoma, or HL, test, or Telo-HL.
Telo-HL is powered by the Company's proprietary TeloView software platform. The purpose of Telo-HL is to stratify HL patients at the point of diagnosis into non-relapsing and relapsing patients so that relapsing patients may be considered for alternative treatments to standard chemotherapy at the beginning of their treatment process. There is currently no biomarker
RelSci News & Alerts gets you: